Last reviewed · How we verify
Xuefu Zhuyu Decoction
Xuefu Zhuyu Decoction, marketed by Jun Li, is an established product in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its approved status and ongoing revenue generation. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Xuefu Zhuyu Decoction |
|---|---|
| Sponsor | Jun Li |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Xuefu-Zhuyu Capsule for the Treatment of "Qizhi Xueyu Zheng" (Qi Stagnation and Blood Stasis Syndrome) (PHASE4)
- Research on the Clinical Effect of Xuefu Zhuyu Decoction in Treating Unstable Angina. (PHASE4)
- Research on the Clinical Effect of Effective Prescription in Treating Unstable Angina. (PHASE4)
- Modulation of Immunity-related Gene Expression Under the Chinese Herbal Formula SS-1 Treatment for Sjögren's Syndrome (PHASE2)
- Evaluation of the Efficacy and the Mechanism of Chinese Herbal Formula SS-1 for Sjögren's Syndrome (PHASE2)
- Study of Herbal Formula Corresponding to Syndrome in Treating Post Percutaneous Coronary Intervention (PCI) Patients With Coronary Heart Disease (CHD) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xuefu Zhuyu Decoction CI brief — competitive landscape report
- Xuefu Zhuyu Decoction updates RSS · CI watch RSS
- Jun Li portfolio CI